Stephen Liu, MD, Georgetown University

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

John V. Heymach, MD, PhD, reviews updated results from the phase III CASPIAN trial for patients with extensive-stage SCLC (small cell lung cancer) as presented at ESMO 2021.

Sandip P. Patel, MD, reviews results and clinical implications from the CASPIAN study, and Heather Wakelee, MD, shares insight on approaching the optimal immunotherapy option for patients with extensive-stage SCLC.

Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.

John V. Heymach, MD, PhD, provides an overview of small cell lung cancer (SCLC), and Ani Balmanoukian, MD, reviews available treatment options for limited-stage disease.

Lung cancer experts provide insight on updates from key clinical trials presented at ESMO 2021 on PD-1 inhibitor–resistant NSCLC.

Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.

Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.

Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.

Sandip P. Patel, MD, reviews updates on dual immunotherapy agents for the treatment of advanced NSCLC including the 4-year update from the CheckMate 227 study.

Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.

Lung cancer experts share updates in the treatment of ALK-mutant NSCLC and KRAS G12C–mutant NSCLC as seen in the CROWN study, BrigALK2 real-world study, and CODEBreaK 100 study.

Heather Wakelee, MD, reviews key data for the treatment of MET exon 14 mutations in NSCLC as seen in the GeoMETry-III trial and the CRYSALIS study.

Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.

Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.

Experts in lung cancer provide insight on recent updates from the ESMO Congress 2021 for the treatment of EGFR-mutant NSCLC.

Vamsidhar Velcheti, MD, and Stephen Liu, MD, discuss their treatment approaches for patients with EGFR-mutant NSCLC who progress on osimertinib.

Heather Wakelee, MD, shares insight on factors to consider when approaching the optimal first-line therapy for patients with EGFR-mutant advanced NSCLC.

Ani Balmanoukian, MD, Sandip P. Patel, MD, and Heather Wakelee, MD, review currently available treatment options for EGFR-mutant advanced NSCLC and discuss their approach to frontline therapy.